- Home
- WERN vs VRDN Comparison
WERN vs VRDN Comparison
Compare WERN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WERN | VRDN |
|---|---|---|
| Founded | 1956 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WERN | VRDN |
|---|---|---|
| Price | $45.64 | $17.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $33.79 | ★ $35.46 |
| AVG Volume (30 Days) | 977.2K | ★ 2.4M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,974,396,000.00 | $5,706,000.00 |
| Revenue This Year | $22.24 | $13.73 |
| Revenue Next Year | $6.33 | $279.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.06 | $13.18 |
| 52 Week High | $46.17 | $34.29 |
Technical Indicators
Market Signals| Indicator | WERN | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 47.55 |
| Support Level | $41.92 | $15.58 |
| Resistance Level | N/A | $18.05 |
| Average True Range (ATR) | 1.47 | 0.91 |
| MACD | 0.10 | -0.17 |
| Stochastic Oscillator | 86.94 | 11.98 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.